These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17323229)

  • 1. Choice of and decreasing of the dosage of risperidone in the treatment of schizophrenia. Global versus individual criteria.
    Gómez-Perretta C
    Actas Esp Psiquiatr; 2007; 35(1):77-8. PubMed ID: 17323229
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of long-acting risperidone.
    Parker G
    Psychiatr Serv; 2005 Jan; 56(1):105-6; author reply 106-7. PubMed ID: 15637203
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.
    Ezewuzie N; Taylor D
    J Psychopharmacol; 2006 Jan; 20(1):86-90. PubMed ID: 16174679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute dystonic reaction with risperidone.
    Takhar J; Manchanda R
    Can J Psychiatry; 1996 Feb; 41(1):61-2. PubMed ID: 8919428
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.
    Kim B; Lee SH; Choi TK; Suh S; Kim YW; Lee E; Yook KH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1231-5. PubMed ID: 18442879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies.
    Lane HY; Chang WH
    J Clin Psychiatry; 1999 Jul; 60(7):487-8. PubMed ID: 10453806
    [No Abstract]   [Full Text] [Related]  

  • 10. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis.
    Cetin M; Ebrinç S; Ağargün MY; Yiğit S
    J Clin Psychiatry; 1999 Aug; 60(8):554. PubMed ID: 10485639
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative effectiveness of antipsychotic drugs.
    Osser DN; Akhter A
    Am J Psychiatry; 2003 Mar; 160(3):590; author reply 592-3. PubMed ID: 12611853
    [No Abstract]   [Full Text] [Related]  

  • 12. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
    Perez V; Cañas F; Tafalla M;
    Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone treatment of an adolescent with severe posttraumatic stress disorder.
    Keeshin BR; Strawn JR
    Ann Pharmacother; 2009 Jul; 43(7):1374. PubMed ID: 19584378
    [No Abstract]   [Full Text] [Related]  

  • 15. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
    Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
    Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 17. Initial dosing strategies for long-acting injectable risperidone.
    Viner MW; Matuszak JM; Knight LJ
    J Clin Psychiatry; 2006 Aug; 67(8):1310-1. PubMed ID: 16965217
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.
    Kim SW; Kim KM; Kim JM; Shin IS; Shin HY; Yang SJ; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):543-5. PubMed ID: 17110011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of long-acting risperidone.
    Pinninti NR; Mago R
    Psychiatr Serv; 2005 Jan; 56(1):105; author reply 106-7. PubMed ID: 15637204
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.